Immuron

$5.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-3.74%) As of 7:24 PM UTC today

Why Robinhood?

You can buy or sell Immuron and other stocks, options, and ETFs commission-free!

About IMRN

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia. The listed name for IMRN is Immuron Limited American Depositary Shares.

CEO
Jerry Kanellos
Employees
—
Headquarters
Carlton, Victoria (VIC)
Founded
1994
Market Cap
38.25M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
87.55K
High Today
$6.29
Low Today
$5.89
Open Price
$6.29
Volume
12.52K
52 Week High
$28.99
52 Week Low
$1.55

IMRN Earnings

Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 19, Pre-Market

You May Also Like

FURY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure